

ASX ANNOUNCEMENT

29 July 2025

APPENDIX 4C AND QUARTERLY ACTIVITY REPORT**AS AT 30 JUNE 2025**

EZZ Life Science Holdings Limited (ASX: EZZ), is a life science company with a mission to improve quality of life and human health. EZZ is passionate about investing in the future of consumer health through the development and distribution of high-quality products via omnichannel models across Australia, New Zealand, China, the United States and other global markets. EZZ presents its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2025 (Q4 FY25).

Highlights

- Successful launch of EZZDAY in the United States with four products now available online via Shopify, supported by US-based manufacturing and FDA registration.
- Entered a new three-year Southeast Asia distribution agreement with ROFA Enterprises, securing a minimum \$21 million in purchase commitments over three years.
- Expanded Australian pharmacy footprint through a partnership with Direct Chemist Outlet, covering up to 130 new pharmacy stores.
- Engaged University of Sydney for a two-year research study on bone health supplements.
- Receipts from customers totalled \$21.3m, representing a 46% increase from the previous quarter.
- Robust operational performance delivered a positive cash inflow of \$1.4 million.
- Cash reserves reached \$20.8m as at 30 June 2025 after paying \$0.9m in dividends during the quarter. The Company remains debt-free, excluding lease liabilities.

Activities**United States Market Entry**

A major strategic milestone was reached by the Company with the official launch of EZZDAY, a US-focused brand supported by local manufacturing and FDA registration. The initial product range includes four health supplements:

- EZZDAY Debloat & Gas Relief Pro (Capsule)
- EZZDAY Vaginal Probiotics & pH Balance (Capsule)
- EZZDAY Triple Anti Solution (NAD+, Multi-Collagen & Resveratrol) (Gummy)
- EZZDAY Colon Detox (Capsule)

All four products are manufactured in the United States to align with consumer preferences, reduce tariffs and freight costs, and enhance supply chain efficiency.

Southeast Asia Expansion

In June, EZZ entered a three-year distribution agreement with ROFA Enterprises Pty. Ltd. (ROFA), securing a minimum purchase value of A\$21 million over the contract term. ROFA will distribute EZZ-branded products across Thailand, Vietnam and Singapore, managing local logistics and marketing, while ensuring compliance with EZZ's brand and operational standards.

This agreement significantly expands EZZ's presence in Southeast Asia, a region of growing consumer demand for premium health supplements.

Domestic Retail Growth

EZZ enhanced its domestic retail footprint via a new partnership with Direct Chemist Outlet (DCO), one of Australia's leading pharmacy chains. Under this agreement, EZZ's flagship products will be stocked in a selection of DCO's 130 stores nationwide. This expansion builds on EZZ's omnichannel model, complementing its online and duty-free presence and over 700 other retail pharmacies across Australia.

Product Innovation and Market Launches

During Q4, EZZ continued to strengthen its innovation pipeline, launching a new consumer health product tailored to further capitalise on EZZ's strong performance in the calcium supplement category. In addition to the EZZDAY-branded products developed for the US market, the Company also launched the following product for key international and domestic markets:

- EZZ Liquid Calcium Soft Gel

This new addition has been well received by consumers and partners alike, reinforcing EZZ's ability to swiftly respond to market demand and maintain a competitive edge.

University of Sydney

During the quarter, EZZ engaged the University of Sydney to undertake in vitro research into the effects of a novel multi-ingredient nutritional supplement on bone growth, as part of a two-year project commencing in April 2025. Led by Associate Professor Zufu Lu and Professor Hala Zreiqat AM from the School of Biomedical Engineering, the study will evaluate a formulation containing key ingredients such as lysine, calcium carbonate, and vitamin D3 using advanced cellular and molecular models. This initiative reinforces EZZ's commitment to evidence-based innovation.

Cash Flow Commentary

Despite seasonal headwinds in Q3 FY25, EZZ rebounded strongly in Q4. Receipts from customers totalled \$21.3m, reflecting a 46% increase from the prior quarter.

EZZ continued to demonstrate strong operating cash flow, generating \$1.4 million for the quarter. This represents a slight decrease from Q3 FY25, primarily due to higher tax payments, which doubled during the period.

Despite paying \$0.9 million in dividends during the quarter, EZZ closed the period with a strong cash balance of \$20.8 million as at 30 June 2025. The Company remains debt-free (excluding lease liabilities), maintaining strong financial flexibility to support future growth initiatives.

Outlook

Looking ahead to FY26, EZZ remains focused on executing its global growth strategy through innovation, market expansion and strong local partnerships. Key priorities for FY26 include:

- Scaling the EZZDAY brand in the US through digital and retail channels, including Amazon and strategic influencer campaigns.
- Driving performance under the ROFA Southeast Asia distribution agreement, with rollouts across Thailand, Vietnam and Singapore.
- Accelerating growth across Australian retail channels via pharmacy partnerships and expanded in-store placement.
- Continuing product innovation aligned with wellness trends and new market needs.
- Continuing to explore targeted acquisition opportunities aligned with long-term growth and shareholder value creation.

With growing brand equity, a clear international roadmap and a robust balance sheet, EZZ is well positioned to capture value in the fast-evolving global health and wellness sector.

EZZ Non-Executive Chair, Glenn Cross, commented:

“Q4 has been a defining period for EZZ, marked by the successful execution of our key growth initiatives across multiple markets. The official launch of our EZZDAY brand in the United States – supported by FDA registrations, local manufacturing, and an initial product range – reflects our strategic commitment to building a sustainable footprint in one of the world’s most important health markets.

“Domestically, our partnership with Direct Chemist Outlet has also enhanced our domestic retail presence, further embedding our products in the everyday lives of Australian consumers and reinforcing our omnichannel growth strategy.

“We were also pleased to secure a high-value, multi-year distribution agreement in Southeast Asia – a region with substantial growth potential and rising demand for premium genomic health products. The ROFA partnership provides a strong platform for deeper market penetration and meaningful brand expansion across Thailand, Vietnam and Singapore.

“As we look ahead to FY26, we remain focused on driving product innovation, scaling our international operations, and delivering strong returns for our shareholders through disciplined execution and strategic foresight.”

Related party payments in the quarter related to:

a.	Purchase of inventory from Australian United Pharmaceuticals Pty Ltd	\$1,146,230
b.	4 months’ rent paid to WM Group Pty Ltd re Lidcombe office/showroom	\$138,233
c.	Fees and reimbursement of travel costs paid to Directors and CEO for the quarter	\$181,519
		\$1,465,982

Cash inflows and outflows are reported on a gross basis, i.e., inclusive of GST.

This notice has been authorised for provision to the ASX by the Board of EZZ Life Science Holdings Limited.

For further information, please contact:**Investor Relations**

<https://www.ezzlife.com.au/investors>

ir@ezzlife.com.au

Annexure

Under Listing Rule 4.7C, the Use of Funds update from the IPO is as follows:

Use of Funds as per Prospectus	Estimated Expenditure (\$ 000')	Actual Expenditure (\$ 000')	Comment
Software development	100	27	Commenced
Additional market expansion	1,375	>1,375	Commenced
Manufacturing facility	2,460	44	Commenced
Research & development	450	529	Commenced
Experimental concept store	800	Nil	To commence
Cost of offer	768	747	Completed
Additional working capital	47	1,580	Commenced
Total	6,000	4,302	

Appendix 4C

Quarterly consolidated cash flow report for entities subject to Listing Rule 4.7B

Name of entity

EZZ Life Science Holdings Limited

ABN

88 608 363 604

Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	21,337	67,146
1.2 Payments for		
(a) research and development	(117)	(192)
(b) product manufacturing and operating costs	(8,462)	(18,715)
(c) advertising and marketing	(9,173)	(36,073)
(d) leased assets	-	-
(e) staff costs	(464)	(1,985)
(f) administration and corporate costs	(753)	(2,779)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	106	417
1.5 Interest and other costs of finance paid	(12)	(28)
1.6 Income taxes paid	(1,034)	(3,449)
1.7 Government grants and tax incentives	-	28
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	1,428	4,370
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	(149)	(286)
(b) businesses	-	-
(c) property, plant and equipment	(67)	(261)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(d) investments	-	-
	(e) intellectual property	1	(17)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Investment in Subsidiaries	-	-
2.6	Net cash from / (used in) investing activities	(215)	(564)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(88)	(355)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	(914)	(1,817)
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(1,002)	(2,172)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	21,055	19,023
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,428	4,370
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(215)	(564)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(1,002)	(2,172)
4.5	Effect of movement in exchange rates on cash held	(417)	192
4.6	Cash and cash equivalents at end of period	20,849	20,849

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	20,849	19,891
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	20,849	19,891

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	1,466
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	1,428
8.2 Cash and cash equivalents at quarter end (item 4.6)	20,849
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	20,849
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

29 July 2025

Date:

The Board of Directors

Authorised by:

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.